Asset Details
Do you wish to reserve the book?
Initial Use of Ambrisentan plus Tadalafil in Pulmonary Arterial Hypertension
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
Initial Use of Ambrisentan plus Tadalafil in Pulmonary Arterial Hypertension
Do you wish to request the book?
Initial Use of Ambrisentan plus Tadalafil in Pulmonary Arterial Hypertension
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Journal Article
Initial Use of Ambrisentan plus Tadalafil in Pulmonary Arterial Hypertension
2015
Overview
Patients with previously untreated pulmonary arterial hypertension who were randomly assigned to combination therapy with ambrisentan and tadalafil had a significantly lower risk of a composite clinical failure outcome at 20 months than did the pooled monotherapy group.
Regardless of the initiating trigger, pulmonary arterial hypertension results in the altered synthesis of a variety of vasoactive substances derived from the endothelium.
1
Current therapies for pulmonary arterial hypertension
2
target abnormalities in one of three intracellular pathways with signaling dysfunction: the prostacyclin, nitric oxide, or endothelin pathway.
1
However, no single class of drug is consistently effective in treating all patients, which suggests that no single pathway plays a dominant pathogenic role.
3
,
4
Combination therapy with agents that target several different pathways may potentially increase the overall therapeutic effect on the mechanisms of this disease
5
and provide additional clinical benefits.
6
– . . .
Publisher
Massachusetts Medical Society
Subject
/ Aged
/ Carbolines - adverse effects
/ Carbolines - therapeutic use
/ Edema
/ Female
/ Headache
/ Humans
/ Hypertension, Pulmonary - drug therapy
/ Hypertension, Pulmonary - mortality
/ Hypertension, Pulmonary - physiopathology
/ Male
/ Natriuretic Peptide, Brain - blood
/ Patients
/ Phenylpropionates - adverse effects
/ Phenylpropionates - therapeutic use
/ Pyridazines - adverse effects
